Combined antithrombin and protein C supplementation in meningococcal purpura fulminans: A pharmacokinetic study

Intensive Care Medicine

Volumn 29, Issue 7, 2003, Pages 1081-1087

  Fourrier, François ^a   Leclerc, Francis ^a   Aidan, Karl ^a   Sadik, Ahmed ^a   Jourdain, Mercé ^a   Tournoys, Antoine ^b   Noizet, Odile ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

Author keywords

Antithrombin; Meningococcemia; Plasma concentrate pharmacokinetics; Protein C; Protein S; Purpura fulminans

Indexed keywords

ACLOTINE; ANTITHROMBIN; PLASMA SUBSTITUTE; PROTEIN C; PROTEIN S;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG HALF LIFE; FULMINATING PURPURA; HUMAN; INFANT; MEASUREMENT; MENINGOCOCCEMIA; SUPPLEMENTATION;

EID: 0042167223     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-003-1784-1     Document Type: Article

References (36)

1. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM (2001) Meningococcal disease. N Engl J Med 344:1378-1388
2. Ten Cate H (2000) Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med 28[Suppl]:S9-S11
3. Faust SN, Heyderman RS, Levin M (2000) Disseminated intravascular coagulation and purpura fulminans secondary to infection. Baillières Clin Haematol 13:179-197
4. Leclerc F, Hazelzet J, Jude B, Hofhuis W, Hue V, Martinot A, Van der Woort E (1992) Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases. Intensive Care Med 18:202-205
5. Founder F, Lestavel P, Chopin C, Marey A, Goudemand J, Rime A (1990) Meningococcemia and purpura fulminans in adults: acute deficiencies of proteins C and S and early treatment with antithrombin III concentrates. Intensive Care Med 16:1-4
6. Fijnvandraat K, Derkx B, Peters M, Bijlmer R, Sturk A, Prins MH, van Deventer SJH, Ten Cate JW (1995) Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict high mortality. Thromb Haemost 75:15-20
7. Founder F, Jourdain M, Tournoys A, Caron C, Goudemand J, Chopin C (1995) Coagulation Inhibitor substitution during sepsis. In: Mediators and inhibitors imbalance in sepsis. A new window for therapeutical interventions. Intensive Care Med 21:S22-S26
8. Gerson WT, Dickerman JD, Bovill EG, Golden E (1993) Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: treatment with protein C concentrate. Pediatrics 91:418-422
9. Rivard GE, David M, Farrell C, Schwarz HP (1995) Treatment of purpura fulminans in meningococcemia with protein C concentrates. J Pediat 126:646-652
10. Smith OP, White B, Vaughan D, Rafferty M, Claffey L, Lyons B, Casey W (1997) Use of protein C concentrate, heparin and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 350:1590-1593
11. Rintala E, Kauppila M, Seppala OP, Voipio-Pulkki LM, Pettila V, Rasi V, Kotilainen P (2000) Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med 28:2373-2378
12. Ettingshausen C, Veldmann A, Beeg T, Schneider W, Jäger G, Kreuz W (1999) Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost 25:537-541
13. Betrosian AP, Balla M, Kofinas G, Papanikolaou M, Georgiadis G (1999) Protein C in the treatment of coagulopathy in meningococcal sepsis. Crit Care Med 27:2849-2850
14. White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP (2000) An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 96:3719-3724
15. Cobcroft R, Henderson A (1994) Meningococcal purpura fulminans treated with antithrombin III concentrate: what is the optimal replacement therapy? Aust NZ J Med 24:575-576
16. Munteanu C, Bloodworth LLO, Korn THE (2000) Antithrombin concentrate with plasma exchange in purpura fulminans. Pediatr Crit Care Med 1:84-87
17. Leclerc F, Leteurtre S, Cremer R, Fourier C, Sadik A (2000) Do new strategies in meningococcemia produce better outcomes? Crit Care Med 28[Suppl]:S60-S636
18. Fourrier F, Jourdain M, Tournoys A, Gosset P, Mangalaboyi J, Chopin C (1998) Effect of a combined antithrombin III and PC substitution in experimental porcine acute endotoxin shock. Shock 10:364-370
19. Martinot A, Leclerc F, Cremer R, Leteurtre S, Fourier C, Hue V (1997) Sepsis in neonates and children: definitions, epidemiology, and outcome. Pediatr Emerg Care 13:277-281
20. Van Brakel MJM, Van Vught AJ, Gemke RJBJ (2000) Pediatric risk of mortality (PRISM) score in meningococcal disease. Eur J Pediatr 159:232-236
21. Comp PC, Doray D, Patton DE, Esmon CT (1986) An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood 67:504-508
22. Fourrier F, Chopin C, Goudemand J, Hendrycxs S, Caron C, Rime A (1992) Septic shock, multiple organ failure and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C and protein S deficiencies. Chest 101:816-823
23. Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P (1997) Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 96:2302-2310
24. Nevière R, Tournoys A, Mordon S, Maréchal X, Song FI, Jourdain M, Fourrier F (2001) Antithrombin reduces mesenteric venular leukocyte interactions and small intestine injury in endotoxemic rats. Shock 15:220-225
25. Dickneite G (1997) The anticoagulant and antiinflammatory effect of antithrombin III in experimental sepsis. Intensive Care Med 23:S58
26. Eisele B, Lamy M, Thijs L, Keinecke H, Schuster H, Matthias F, Fourrier F, Heinrichs H, Delvos U (1998) Antithrombin III in patients with severe sepsis: a randomized placebo-controlled double blind multicenter trial plus a meta-analysis on all randomized placebo-controlled multicenter trials with antithrombin III in severe sepsis. Intensive Care Med 24:663-672
27. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chzalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Joers M, Bone RC, Opal S (2001) High-dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA 286:1869-1878
28. Depalo V, Kessler C, Opal S (2001) Success or failure in phase III sepsis trials: comparisons between the Drotrecogin alfa (activated) and Antithrombin III clinical trials. Adv Sepsis 1:114-124
29. Fourrier F, Jourdain M, Tournoys A (2000) Clinical trial results with antithrombin III in sepsis. Crit Care Med 28[Suppl]:S38-S44
30. Esmon CT (2000) The protein C Pathway. Crit Care Med 28 [Suppl]:S44-S48
31. Taylor FB Jr, Peer GT, Lockhart MS, Ferrell G, Esmon CT (2001) Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 97:1685-1688
32. Faust SN, Heyderman RS, Levin M (2001) Coagulation in severe sepsis: a central role for thrombomodulin and activated protein C. Crit Care Med 29[Suppl]:S62-S68
33. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, Laszik Z, Esmon CT, Heyderman RS (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345:408-416
34. Yan B, Dhainaut JF (2001) Activated protein C versus protein C in severe sepsis. Crit Care Med 29[Suppl]:S69-S74
35. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez AS, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709
36. Hazelzet JA, De Kleijn ED, De Groot R (2001) Endothelial protein C activation in meningococcal sepsis. N Engl J Med 345:1776-1777